Approach and management of checkpoint inhibitor-related immune hepatitis

J Gastrointest Oncol. 2018 Feb;9(1):220-224. doi: 10.21037/jgo.2017.08.14.

Abstract

Immune checkpoint inhibitors have promising clinical activity across multiple gastrointestinal cancers and immune-mediated hepatotoxicity is particularly relevant for this group of patients. In this article we will review the recognition, workup and management of suspected checkpoint inhibitor related immune-hepatitis.

Keywords: Immunotherapy; gastrointestinal cancers; immune checkpoint inhibitors; immune-mediated toxicity.